BiomX acquires 60% of defense tech firm DFSL for $750K cash, $3M note, and ~5.5M shares

BiomX completed the acquisition of 60% of DR. Frucht Systems Ltd. (DFSL), a laser radar security systems company, by purchasing all of Mandragola's shares in DFSL. The transaction closed immediately upon execution on April 13, 2026, making DFSL a majority-owned subsidiary of BiomX.

BiomX is acquiring a 29-year-old defense technology company focused on laser radar detection systems for drones, perimeter security, surveillance, and transportation safety. This represents a significant business pivot for BiomX, which was previously focused on microbiome therapeutics, into the defense and security technology sector.

The seller Mandragola committed to provide BiomX with a credit facility for DFSL operations and debt repayment, though specific terms and amounts are not yet finalized. This suggests DFSL may have existing debt obligations and will require additional capital for business development.

The company disclosed completion of an acquisition or disposition of assets under Item 2.01. The filing references Item 1.01 for details, but Item 1.01 content was not provided in this excerpt. This typically indicates a material transaction has closed, such as a business combination, asset sale, or divestiture.

BiomX completed a private placement with Mandragola involving 923,000 common shares plus a convertible note, pre-funded warrants, and five-year warrants. The transaction was conducted under exemptions from registration requirements, meaning these securities were not registered with the SEC and cannot be freely resold without registration or an exemption. This represents potential dilution to existing shareholders once the note converts and warrants are exercised.

BiomX disclosed it has executed a stock purchase agreement to acquire Nimbus. The 8-K references a press release with details but does not provide transaction terms, purchase price, or strategic rationale in the filing itself.

The forward-looking statements section references plans to integrate DFSL as a majority-owned operating subsidiary. This suggests a separate transaction or related acquisition involving DFSL, though details are not provided in the main disclosure items.

BiomX plans to seek stockholder approval for issuing common stock related to securities issued to an entity called Mandragola. This indicates the transaction involves equity consideration that requires shareholder vote, likely due to listing rules or ownership dilution thresholds.

The transaction requires approval from the IIA (likely Israel Innovation Authority) for a change of control of DFSL. This regulatory approval is a closing condition, and failure to obtain it is identified as a risk factor that could prevent deal completion.

Mandragola is expected to provide a credit line to BiomX, suggesting this entity is both a securities holder and potential lender. This financing arrangement appears connected to the broader transaction structure but specific terms are not disclosed.

BiomX issued a $3 million unsecured convertible promissory note to Mandragola Ltd. on April 6, 2026. Convertible notes allow the lender to convert debt into equity, typically at a discount, which can dilute existing shareholders. The unsecured nature means no collateral backs the obligation.

BiomX issued a pre-funded warrant to Mandragola Ltd. on April 6, 2026. Pre-funded warrants are typically exercisable immediately at a nominal price, functioning almost like common stock but with minor tax or regulatory advantages for the holder. This represents potential immediate dilution to existing shareholders.

BiomX issued a five-year warrant to Mandragola Ltd. on April 6, 2026. This gives the holder the right to purchase additional shares at a set price over the next five years, representing potential future dilution if exercised.

BiomX entered a stock purchase and assignment agreement with Mandragola Ltd. on April 13, 2026. The specific terms are not disclosed in this 8-K body, but such agreements typically involve the sale of equity or transfer of rights, potentially affecting ownership structure.